Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Splicing factor 3B subunit 3 (SF3B3), also known as SAP130, is a core component of the SF3B complex, which is an essential part of the U2 small nuclear ribonucleoprotein (snRNP) involved in pre-mRNA splicing (UniProt Q15393). It plays a critical role in the early stages of spliceosome assembly by helping to stabilize the interaction between the U2 snRNP and the branch point sequence of the intron (PubMed: 10323865). Beyond its role in splicing, SF3B3 is also a member of the STAGA transcription coactivator-complex, linking mRNA processing with chromatin remodeling and transcriptional regulation (PubMed: 11564863). In oncology, SF3B3 is frequently overexpressed and serves as a prognostic marker in several malignancies, including breast and liver cancers, where it promotes cell proliferation and survival by modulating the splicing of key oncogenic transcripts (PubMed: 25851150). It has been identified as a potential therapeutic target because its depletion or inhibition leads to significant alterations in alternative splicing and reduced tumor growth (PubMed: 28431239). While most small-molecule splicing inhibitors like E7107 and pladienolides primarily bind to the SF3B1 subunit, SF3B3 is an integral structural and functional member of the targeted SF3B complex (PubMed: 17510415). Disruption of SF3B3 function results in the accumulation of unspliced pre-mRNAs and the induction of apoptosis in cancer cells, making it a focus for developing next-generation spliceosome modulators. Additionally, SF3B3 acts as a damage-associated molecular pattern (DAMP) when released from necrotic cells, interacting with the Mincle receptor to trigger inflammatory responses (PubMed: 18480830). Overall, SF3B3 represents a multifaceted target at the intersection of RNA processing, gene expression, and cancer progression.
Inhibition of the SF3B complex within the U2 snRNP, leading to the disruption of branch point recognition and modulation of alternative splicing.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Splicing factor 3B subunit 3 (SF3B3) (SF3B3).